BR112018006276A2 - composto, composição farmacêutica, e, inibidor de subunidade gyrb da dna girase e/ou subunidade pare de topoisomerase iv. - Google Patents

composto, composição farmacêutica, e, inibidor de subunidade gyrb da dna girase e/ou subunidade pare de topoisomerase iv.

Info

Publication number
BR112018006276A2
BR112018006276A2 BR112018006276-6A BR112018006276A BR112018006276A2 BR 112018006276 A2 BR112018006276 A2 BR 112018006276A2 BR 112018006276 A BR112018006276 A BR 112018006276A BR 112018006276 A2 BR112018006276 A2 BR 112018006276A2
Authority
BR
Brazil
Prior art keywords
subunit
topoisomerase
dna
gyrb
compound
Prior art date
Application number
BR112018006276-6A
Other languages
English (en)
Inventor
Kumar Khera Manoj
Mathur Tarun
A. Sattigeri Jitendra
Masuda Nobuhisa
Soneda Tsuyoshi
Kagoshima Yoshiko
Konosu Toshiyuki
Suzuki Tetsuya
Yamaoka Makoto
Itooka Ryo
Original Assignee
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Company, Limited filed Critical Daiichi Sankyo Company, Limited
Publication of BR112018006276A2 publication Critical patent/BR112018006276A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

problema a ser resolvido. há uma necessidade por um novo antibiótico tendo um novo mecanismo de ação que exibe forte atividade antibacteriana não apenas contra bactéria sensível, mas também contra bactéria resistente ao mesmo e ao mesmo tempo possua solubilidade excelente e perfil de segurança passível ao uso humano. solução para o problema. como um resultado de pesquisa intensiva, os presentes inventores verificaram que um composto representado pela fórmula geral (i), um estereoisômero ou um sal farmaceuticamente aceitável do mesmo inibe a subunidade gyrb da dna girase e/ou a subunidade pare de topoisomerase iv, possui solubilidade excelente e perfil de segurando para uso em humanos para o tratamento de doenças infecciosas bacterianas.
BR112018006276-6A 2015-09-30 2016-09-28 composto, composição farmacêutica, e, inibidor de subunidade gyrb da dna girase e/ou subunidade pare de topoisomerase iv. BR112018006276A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3119/DEL/2015 2015-09-30
IN3119DE2015 2015-09-30
PCT/IB2016/055795 WO2017056012A1 (en) 2015-09-30 2016-09-28 Hydroxyalkyl thiadiazole derivatives

Publications (1)

Publication Number Publication Date
BR112018006276A2 true BR112018006276A2 (pt) 2018-10-16

Family

ID=57218949

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018006276-6A BR112018006276A2 (pt) 2015-09-30 2016-09-28 composto, composição farmacêutica, e, inibidor de subunidade gyrb da dna girase e/ou subunidade pare de topoisomerase iv.

Country Status (19)

Country Link
US (1) US10399968B2 (pt)
EP (1) EP3356361B1 (pt)
JP (1) JP6824256B2 (pt)
KR (1) KR20180054650A (pt)
CN (1) CN108137574B (pt)
AU (1) AU2016330271B2 (pt)
BR (1) BR112018006276A2 (pt)
CA (1) CA2999982C (pt)
CO (1) CO2018003548A2 (pt)
ES (1) ES2817749T3 (pt)
HK (1) HK1252275A1 (pt)
IL (1) IL258411B (pt)
MX (1) MX2018003562A (pt)
MY (1) MY184406A (pt)
PH (1) PH12018500697A1 (pt)
RU (1) RU2737892C1 (pt)
TW (1) TW201731844A (pt)
WO (1) WO2017056012A1 (pt)
ZA (1) ZA201801718B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2737892C1 (ru) * 2015-09-30 2020-12-04 Дайити Санкио Компани, Лимитед Гидроксиалкилтиадиазольные производные
TW201840322A (zh) * 2017-03-14 2018-11-16 日商第一三共股份有限公司 羥烷基噻二唑衍生物之ｎ－膦醯基氧基甲基前驅藥
US20210323957A1 (en) 2018-09-03 2021-10-21 Univerza V Ljubljani New class of dna gyrase and/or topoisomerase iv inhibitors with activity against gram-positive and gram-negative bacteria
WO2022129327A1 (en) 2020-12-17 2022-06-23 Univerza V Ljubljani New n-phenylpyrrolamide inhibitors of dna gyrase and topoisomerase iv with antibacterial activity
CN115466246B (zh) 2021-06-11 2024-02-06 中国医学科学院药物研究所 吡咯酰哌啶胺类化合物及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
US20080161306A1 (en) 2005-02-18 2008-07-03 Brian Sherer Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors
CN101163693B (zh) 2005-02-18 2013-03-06 阿斯利康(瑞典)有限公司 抗菌哌啶衍生物
CN101163697A (zh) 2005-02-18 2008-04-16 阿斯利康(瑞典)有限公司 作为dna促旋酶和拓扑异构酶抑制剂的吡咯衍生物
EP1861393A2 (en) 2005-03-04 2007-12-05 AstraZeneca AB Pyrrole derivatives as dna gyrase and topoisomerase inhibitors
US20090253671A1 (en) 2005-03-04 2009-10-08 Astrazeneca Ab Tricyclic derivatives of azetidine and pyrrole with antibacterial activity
BRPI0620196A2 (pt) 2005-12-23 2013-01-15 Astrazeneca Ab composto, processo para a preparaÇço do mesmo, composiÇço farmacÊutica, uso de um composto, e, mÉtodos para a produÇço de um efeito antibacteriano em um animal de sangue quente, para a inibiÇço de dna girase e/ou topoisomerase iv bacteriana em um animal de sangue quente e para o tratamento de uma infecÇço bacteriana em um animal de sangue quente
WO2008020227A2 (en) 2006-08-17 2008-02-21 Astrazeneca Ab Antibacterial pyrrolecarboxamides
TW200819437A (en) 2006-08-17 2008-05-01 Astrazeneca Ab Chemical compounds
WO2008020229A2 (en) 2006-08-17 2008-02-21 Astrazeneca Ab Antibacterial pyrrolecarboxamides
TW200906412A (en) 2007-06-12 2009-02-16 Astrazeneca Ab Piperidine compounds and uses thereof
TWI498115B (zh) * 2007-12-27 2015-09-01 Daiichi Sankyo Co Ltd 咪唑羰基化合物
CA2732618A1 (en) 2008-07-30 2010-02-04 Ranbaxy Laboratories Limited Pyrrole carboxylic acid derivatives as antibacterial agents
TW201026694A (en) 2008-12-12 2010-07-16 Astrazeneca Ab Compound 468
TW201026695A (en) 2008-12-12 2010-07-16 Astrazeneca Ab Piperidine compounds and uses thereof-596
JP2011026305A (ja) * 2009-06-24 2011-02-10 Daiichi Sankyo Co Ltd イミダゾールカルボニル化合物を含有する医薬組成物
EP2906216B1 (en) 2012-10-10 2020-06-24 Kumar, Ajay Inhibitors of dna gyrase for the treatment of bacterial infections
RU2737892C1 (ru) * 2015-09-30 2020-12-04 Дайити Санкио Компани, Лимитед Гидроксиалкилтиадиазольные производные

Also Published As

Publication number Publication date
ES2817749T3 (es) 2021-04-08
IL258411A (en) 2018-05-31
KR20180054650A (ko) 2018-05-24
RU2737892C1 (ru) 2020-12-04
AU2016330271A1 (en) 2018-04-12
US20180327399A1 (en) 2018-11-15
IL258411B (en) 2021-08-31
CA2999982A1 (en) 2017-04-06
AU2016330271B2 (en) 2020-04-30
HK1252275A1 (zh) 2019-05-24
CA2999982C (en) 2020-07-28
PH12018500697A1 (en) 2018-10-01
WO2017056012A1 (en) 2017-04-06
JP2018529696A (ja) 2018-10-11
CN108137574A (zh) 2018-06-08
MY184406A (en) 2021-04-01
EP3356361A1 (en) 2018-08-08
US10399968B2 (en) 2019-09-03
TW201731844A (zh) 2017-09-16
CN108137574B (zh) 2021-12-28
CO2018003548A2 (es) 2018-07-19
EP3356361B1 (en) 2020-07-08
MX2018003562A (es) 2018-06-19
ZA201801718B (en) 2019-01-30
JP6824256B2 (ja) 2021-02-03

Similar Documents

Publication Publication Date Title
BR112018006276A2 (pt) composto, composição farmacêutica, e, inibidor de subunidade gyrb da dna girase e/ou subunidade pare de topoisomerase iv.
BR112018000906A2 (pt) ?composto, medicamento, métodos de inibição da histona desacetilase em um mamífero, e para a profilaxia ou o tratamento de doenças, e, uso de um composto?
BR112017011923A2 (pt) bactéria modificada para tratar doenças associadas com hiperamonemia
BR112019002576A2 (pt) composto, medicamento¸ métodos para inibição de gcn2 em um mamífero e para a profilaxia ou tratamento de câncer em um mamífero, e, uso do composto ou um sal do mesmo
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
NI201900099A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CR20110077A (es) Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
UY37742A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19070413A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CR20180496A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112015030399B8 (pt) Derivados heterocíclicos, uso dos referidos derivados e composição farmacêutica para a prevenção ou tratamento de doenças associadas com a ativação da proteína stat3
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112015017519A2 (pt) compostos e métodos para o tratamento de infecções bacterianas
PH12016501988A1 (en) Antibacterial compounds
BR112019022307A2 (pt) Derivados da pirrolopirimidina úteis como inibidores de replicação de vírus da influenza.
BR112016016130A2 (pt) Compostos e métodos
CO2018001237A2 (es) Derivados de apramicina efectivos contra bacterias resistentes a múltiples fármacos y composiciones de los mismos
BR112021018815A2 (pt) Gepotidacina para uso no tratamento de infecções bacterianas do trato urinário
CL2017001276A1 (es) Derivados de benzotiazol antibacterianos
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
BR112019024549A2 (pt) compostos derivados de glicopeptídeo e usos dos mesmos
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
BR112017015744A2 (pt) composto apresentando uma estrutura de fórmula (i), um sal farmaceuticamente aceitável do mesmo ou um isômero ótico do mesmo, composição farmacêutica e uso do composto de fórmula (i) para o tratamento e prevenção de mycobacterium tuberculosis ou outras infecções microbianas
BR112017001803A2 (pt) aril-hidrazidas contendo uma fração de 2-piridona como agentes antibacterianos seletivos

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]